Candriam S.C.A. Adverum Biotechnologies, Inc. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 20, 2021	SELL	$3.36 - $10.56 $1 Million - $3.15 Million	-298,492 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$9.84 - $14.26 $50,016 - $72,483	-5,083 Reduced 1.67%	298,492 $3.24 Million
Q3 2020 Oct 19, 2020	BUY	$10.3 - $21.64 $772,500 - $1.62 Million	75,000 Added 32.81%	303,575 $3.13 Million
Q2 2020 Jul 23, 2020	BUY	$8.53 - $25.64 $243,744 - $732,663	28,575 Added 14.29%	228,575 $4.77 Million
Q4 2019 Jan 21, 2020	BUY	$5.12 - $12.22 $1.02 Million - $2.44 Million	200,000 New	200,000 $2,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.